This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Phreesia (PHR) Moves 13.9% Higher: Will This Strength Last?
by Zacks Equity Research
Phreesia (PHR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
CLOV Q3 Estimates Unchanged Before Earnings: How to Play the Stock?
by Zacks Equity Research
The continued strength in Clover Health's offerings is likely to have driven the company's performance in the third quarter.
HIMS Q3 Estimates Unchanged Before Earnings: How to Play the Stock?
by Zacks Equity Research
The continued solid uptake of Hims & Hers offerings and expanding subscriber base are likely to have driven the company's performance in the third quarter.
Down -10.25% in 4 Weeks, Here's Why Phreesia (PHR) Looks Ripe for a Turnaround
by Zacks Equity Research
Phreesia (PHR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Teladoc Stock Near 52-Week Low: Is it Healthy Enough to Invest?
by Zacks Equity Research
TDOC is well positioned to grow in the long run on the back of expanding product offerings, memberships, AI integration, business diversification and global expansions.
Phreesia (PHR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Phreesia (PHR) give insight into how the company performed in the quarter ended July 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Phreesia (PHR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of 16.22% and 0.35%, respectively, for the quarter ended July 2024. Do the numbers hold clues to what lies ahead for the stock?
Phreesia (PHR) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Get a deeper insight into the potential performance of Phreesia (PHR) for the quarter ended July 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Augmedix, Inc. (AUGX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Augmedix (AUGX) delivered earnings and revenue surprises of -33.33% and 0.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
P3 Health Partners Inc. (PIII) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
P3 Health Partners (PIII) delivered earnings and revenue surprises of -87.50% and 4.02%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Nyxoah SA (NYXH) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Nyxoah (NYXH) delivered earnings and revenue surprises of -2.22% and 56.88%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Think Phreesia (PHR) Could Surge 27.77%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 27.8% in Phreesia (PHR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Phreesia (PHR) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Phreesia (PHR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include CLEAR Secure (YOU), Applied DNA Sciences (APDN), Phreesia (PHR), Vigil Neuroscience (VIGL) and Biodesix (BDSX).
5 Medical Info Systems Stock to Buy for a Stable Portfolio
by Nalak Das
We have narrowed our search to five medical info systems stocks. These are: HIMS, ENOV, LUNG, PHR, LAB.
Here's Why Phreesia (PHR) is Poised for a Turnaround After Losing -18.25% in 4 Weeks
by Zacks Equity Research
Phreesia (PHR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Compared to Estimates, Phreesia (PHR) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Phreesia (PHR) give a sense of how its business performed in the quarter ended April 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Phreesia (PHR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of 31.37% and 0.20%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?
Unlocking Q1 Potential of Phreesia (PHR): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Phreesia (PHR), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended April 2024.
Talkspace, Inc. (TALK) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Talkspace (TALK) delivered earnings and revenue surprises of 50% and 2.52%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Stock Market News for Mar 18, 2024
by Zacks Equity Research
Wall Street closed lwer on Friday with the Fed facing an inflation dilemma ahead of the policy meeting.
Phreesia (PHR) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Phreesia (PHR) give a sense of how its business performed in the quarter ended January 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Phreesia (PHR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of 3.45% and 2.01%, respectively, for the quarter ended January 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Phreesia (PHR) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Phreesia (PHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.